Results 1 to 10 of about 38,837 (270)

Second-generation antipsychotics and metabolic syndrome: a role for mitochondria [PDF]

Frontiers in Psychiatry, 2023
Psychosis is a known risk factor for developing metabolic syndrome (MetS). The risk is even greater in patients who are taking second-generation antipsychotics (SGAs).
Katherine R. H. Mortimer, Mohammed Zia Ul Haq Katshu, Mohammed Zia Ul Haq Katshu, Lisa Chakrabarti   +3 more
doaj   +4 more sources

Use of second-generation antipsychotics in autism spectrum disorder: a systematic review and meta-analysis protocol [PDF]

BMJ Open, 2023
Introduction Atypical antipsychotics have been studied to treat autism spectrum disorder (ASD). However, like little is known about whether these drugs are effective and safe when compared in controlled and non-controlled settings.
Cristiane de Cássia Bergamaschi, Luciane Cruz Lopes, Izabela Fulone, Mabel Fernandes Figueiró, Lauren Giustti Mazzei, Jardel Corrêa de Oliveira, Luis Phillipe Nagem Lopes, Elisangela da Costa Lima, Flávia Casale Abe   +8 more
doaj   +4 more sources

A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics

Archives of Mental Health, 2020
Introduction: The prevalence of metabolic syndrome is more in patients with schizophrenia receiving first- and second-generation antipsychotics. Aim and Objectives: The aim is to study the prevalence of metabolic syndrome in patients with schizophrenia ...
Dinesh Panati, T P Sudhakar, Puthalapattu Swetha, Vinay Kumar Sayeli   +3 more
doaj   +2 more sources

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics? [PDF]

Biomedicines, 2022
Schizophrenia (SCZ) is a complex psychiatric disorder of multifactorial origin, in which both genetic and environmental factors have an impact on its onset, course, and outcome.
Olga Płaza, Piotr Gałecki, Agata Orzechowska, Małgorzata Gałecka, Justyna Sobolewska-Nowak, Agata Szulc   +5 more
doaj   +2 more sources

Neutropenia induced by several second-generation antipsychotics :A case report [PDF]

European Psychiatry, 2023
Introduction Antipsychotic medications remain the mainstay of the treatment of various psychiatric disorders, particularly schizophrenia. However, this therapeutic class can induce a range of side effects.
H. Zarouf, M. Chtibi, S. Belbachir, A. Ouanass   +3 more
doaj   +2 more sources

Combination treatment with second generation antipsychotics other than clozapine [PDF]

European Psychiatry, 2021
Background Antipsychotic combination treatment without clozapine is common in the treatment of schizophrenia patients worldwide, despite clinical guidelines generally do not recommend such practice.
C. Schmidt-Kraepelin
doaj   +2 more sources

Cerebral Computed Tomographic Findings in Schizophrenia: Relationship to Second-Generation Antipsychotics and Hyperprolactinemia. [PDF]

Healthcare (Basel)
Petric PS, Ifteni P, Popa AV, Teodorescu A.   +3 more
europepmc   +3 more sources

Sex differences in side effects of second-generation antipsychotics [PDF]

Annals of General Psychiatry, 2008
Paterakis Perikles, Sardis Andreas, Leotsakou Christina   +2 more
doaj   +2 more sources

First exposure to second-generation antipsychotics alters gut microbiota and metabolic profiles in patients with glucose-lipid metabolism disorders. [PDF]

Front Psychiatry
Wu Y, Zang S, Wu Z, Huang J.
europepmc   +3 more sources

Serum Apolipoprotein B Levels and Apolipoprotein B/Apolipoprotein A1 Ratio as Predictors of Dyslipidemia Risk in Patients Treated with Second-Generation Antipsychotics: A Retrospective Cohort Study. [PDF]

Neuropsychiatr Dis Treat
Zhang JX, Huang ZQ, Yang JM, Wang WY, Li WN.   +4 more
europepmc   +3 more sources